Skip to content

UroGen Pharma URGN EPS (Diluted)

Discontinued — last reported Q2 '21

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
Pfizer logo
PfizerPFE
$0.47-9.6%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.14-52.9%
Merck & Co. logo
Merck & Co.MRK
-$1.72-186%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.62-313%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
-$0.64-36.2%

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.71B+71.7%
Enterprise value$1.8B+80.9%
P/S12.2×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasicAndDiluted.

The official record: UroGen Pharma’s 10-Q, filed August 4, 2021, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's EPS (diluted)?
UroGen Pharma (URGN) reported EPS (diluted) of -$1.17 in Q2 2021.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.